MedVector

The company’s Prime-Control Technology is designed to help study teams expand their subject enrollment beyond the reach of their clinical trial sites.

March 25, 2021 – MedVector has begun the rollout of its Prime-Controltm Technology, to give contract research organizations (CROs) and pharma sponsors access to patients without triggering new clinical trial sites.

MedVector introduces its Prime-Controltm Technology to provide contract research organizations and pharmaceutical sponsors with access to subjects for new clinical trials.

Last year, pharmaceutical giant Gilead Sciences came under fire for testing its coronavirus vaccine on a sample of people that didn’t accurately reflect those largely devastated by it — the elderly, the poor and Latino communities.

Scott Stout enjoys competing in downhill mountain biking, riding motorcycles, and business.

StartEngine is an equity crowdfunding platform that offers secondary trading in startup shares.

Craig Lipset joined MedVector as a board member and executive advisor. MedVector's Prime-Control Technology platform provides access to millions of potential clinical trial participants.

Listen to CEO and Co-Founder, Scott Stout on The Huxley Morton Podcast – Series 2, Episode 8.

MedVector appointed John Neal, founder and chairman of PCRS Network, as strategic advisor for pharma relations and clinical protocol. MedVector partners with CROs, sponsors, and patient recruitment companies to expand trial participation.

Craig Lipset designed and co-led a fully virtual clinical trial, advises pharmaceutical companies and the Innovative Medicines Initiative in Europe on decentralized trials, and co-chairs the Decentralized Trials & Research Alliance.

John Neal is founder and chairman of PCRS Network, a group of independently owned and operated Phase I, II, and III clinical research sites across the U.S. that conduct studies in a wide range of indications.

Kelly Chu has led technology initiatives for more than 20 years and is co-founder and CEO/CTO of Sierra Labs, which automates compliance in regulated markets. He previously led the technology team at Science 37.

Moze Cowper, recognized for his work with pharmaceutical and medical device companies, is the former lead counsel for Amgen, where his role included providing training and business advice to clients on negotiation of clinical trial agreements, consent forms, study protocols, and licensing deals.

The CRPN Central Podcast episode discusses diversity and inclusion in clinical research with Dr. Fox, a site advocate, and solution innovators.